Whether $1 or $10 it will have the same market cap.
For example, Far has a MC of 320M @ 10c. For FAR to reach $1 now it would have a MC of approx $3.2B, as it now stands because thats how many shares are on issue - 3.2B.
If they do a CR pre appraisal and issue 300M more shares, so 3.5B shares on issue, Far now have to reach a MC of $3.5B to give you that same $1 SP, hence the reason for most people wanting as little dilution as possible, me included.
If FAR do lets say for ease of calculations a 10/1 consolidation at 10c. SP will go to $1. Shares on issue will be 320M, 3.2B shares will be divided by 10 but your MC remains the same $320M.
So realistically there should be no reason for it to be harder to get to $1 now as opposed to $10 after a consolidation, its the same percentage gain, the company will still be valued the same, its dilution that makes it harder to reach a figure you have in mind.
Just because a companies SP is high doesn't mean its a better company or a more valuable company e.g Two good companies, Telstra valued at $72B with a SP of $6 and Dominos pizza with a SP of $36.50 and a MC of $3B.
- Forums
- ASX - By Stock
- FAR
- consolidation
consolidation, page-12
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.5¢ |
Change
-0.010(1.98%) |
Mkt cap ! $46.20M |
Open | High | Low | Value | Volume |
50.5¢ | 50.5¢ | 49.5¢ | $26.45K | 52.95K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 21299 | 49.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 4159 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 21299 | 0.495 |
2 | 3995 | 0.485 |
2 | 28930 | 0.480 |
2 | 70000 | 0.475 |
2 | 78150 | 0.470 |
Price($) | Vol. | No. |
---|---|---|
0.500 | 4159 | 3 |
0.505 | 1852 | 2 |
0.510 | 59999 | 2 |
0.525 | 69690 | 1 |
0.530 | 30000 | 1 |
Last trade - 15.29pm 15/07/2024 (20 minute delay) ? |
Featured News
FAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online